

Roche and Genentech doubles investment to \$2 billion for manufacturing site in Holly Springs, North Carolina – January 23, 2026

Facility to support production of obesity portfolio; began construction in August 2026 and expected to be operational in 2029

Genentech, a member of the Roche Group, [announced](#) this week that it will nearly triple its investment in a new manufacturing facility in Holly Springs, North Carolina. The total investment will now reach ~\$2 billion and expand the production capacity of a facility focused on cardiometabolic portfolio.

Roche and Genentech first announced the initial \$700 million investment in [May 2025](#). The companies broke ground in [August 2025](#), and the facility is expected to be operational by 2029. [Previously](#), Roche CEO Ms. Theresa Graham said that Holly Springs site will serve as a “high-volume, high throughput facility” to support the growing obesity portfolio.

The expanded investment will add ~100 new jobs in North Carolina and support a total of 500 high-wage manufacturing jobs and 1,500 construction jobs.

Table of Contents

1. [Roche has committed \\$50 billion to US manufacturing by 2030](#)
2. [Roche’s obesity pipeline includes incretin-based candidates and Zealand-partnered amylin agonist petrelintide](#)
3. [Close Concerns’ Questions](#)

Roche has committed \$50 billion to US manufacturing by 2030

In [April 2025](#), Roche announced a \$50 billion investment in its US operations from 2025-2030 to significantly expand its footprint across manufacturing, research, and innovation. Currently, Roche has 13 manufacturing and 15 R&D sites in the US.

Plans include a \$550 million investment to expand its existing Indianapolis Diagnostics campus to support manufacturing for Accu-Chek SmartGuide CGM. Of note, the Accu-Chek SmartGuide CGM is [available](#) in Germany, the Netherlands, and Switzerland, and is currently under [regulatory discussions](#) with the FDA.

In [May 2025](#), Genentech also announced plans to invest over \$700 million to build a 700,000-square-foot manufacturing facility in Holly Springs, which will produce [next-generation](#) obesity therapies currently in development. Construction began in [August 2025](#).

Other plans include:

- Expansions to manufacturing and distribution capacity in Kentucky, Indiana, New Jersey, Oregon, and California;
- Expansions to existing R&D centers in Arizona, Indiana, and California;
- Construction of a [new center](#) for AI and cardiovascular, renal and metabolism research based in Massachusetts; and
- A new gene therapy manufacturing plant in Pennsylvania.

Roche’s obesity pipeline includes incretin-based candidates and Zealand-partnered amylin agonist petrelintide

Roche has expanded its obesity pipeline over the past few years, including through a \$2.7 billion acquisition of Carmot

Therapeutics in [December 2023](#) and a \$1.65 billion partnership with Zealand Pharma in [March 2025](#). Roche's [key candidates](#) include:

- (i) petrelintide, a long-acting amylin analog, currently evaluated in phase 2 [ZUPREME-1](#) (n=494) and [ZUPREME-2](#) (n=216) trials for people with overweight or obesity without and with T2D, respectively;
- (ii) CT-388, once-weekly dual GLP-1/GIP RA, studied in phase 2 trials for people with obesity [with](#) (n=360) or [without](#) T2D (n=450);
- (iii) CT-996, once-daily oral GLP-1 RA, assessed in a [phase 2](#) trial (n=340) in people with overweight or obesity; and
- (iv) CT-868, once-daily dual GLP-1/GIP RA, which may advance to phase 3 for T1D with a BMI of 25 kg/m² or greater.

At [JPM 2026](#), Ms. Graham said Roche will deliver the “next innovation cycle” in the cardiometabolic field, especially through its obesity pipeline.

Close Concerns' Questions

1. How far is Roche from its goal of \$50 billion investment by 2030?
2. How will the additional \$1.3 billion investment expand the space, production capacity, and efficiency of the manufacturing site in Holly Springs?

--by Kat Moon, Jeremy Alkire, and Kelly Close